NCT04676633View on ClinicalTrials.gov

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

January 13, 2023

Study Completion Date

January 13, 2023

Conditions
Hepatocellular CarcinomaLiver MetastasesCholangiocarcinoma
Interventions
DRUG

STP705

Investigational Product

Trial Locations (4)

40202

Norton Cancer Institute, Louisville

85258

Honor Health, Scottsdale

90033

USC Norris Comprehensive Cancer Center, Los Angeles

07960

Atlantic Health System, Morristown

Sponsors

Lead Sponsor

Sirnaomics
All Listed Sponsors
collaborator

Translational Drug Development

OTHER

lead

Sirnaomics

INDUSTRY

NCT04676633 - Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy | Biotech Hunter | Biotech Hunter